Recombinant bivalent respiratory syncytial virus vaccine - Beijing Health Guard Biotechnology
Alternative Names: Recombinant bivalent RSV vaccine - Beijing Health Guard BiotechnologyLatest Information Update: 16 Feb 2024
At a glance
- Originator Beijing Health Guard Biotechnology
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 08 Feb 2024 Beijing Health Guard Biotechnology plans to submit an IND application for Respiratory-syncytial-virus-vaccines in 2024 (Beijing Health Guard Biotechnology pipeline, February 2024)
- 08 Feb 2024 Beijing Health Guard Biotechnology plans a clinical trial for Respiratory syncytial virus infections (Prevention) (Beijing Health Guard Biotechnology pipeline, February 2024)
- 06 Jan 2023 Preclinical trials in Respiratory syncytial virus infections (Prevention) in China (Parenteral), prior to January 2023 (Beijing Health Guard Biotechnology pipeline, January 2023)